Search Results - "Oerlemans, M. I. F. J."

Cardiac amyloidosis: the need for early diagnosis by Oerlemans, M. I. F. J., Rutten, K. H. G., Minnema, M. C., Raymakers, R. A. P., Asselbergs, F. W., de Jonge, N.

“…Amyloidosis is a collection of systemic diseases characterised by misfolding of previously soluble precursor proteins that become infiltrative depositions,…”
Get full text

Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker? by Tingen, H. S. A., Tubben, A., Bijzet, J., van den Berg, M. P., van der Meer, P., Houwerzijl, E. J., Muntinghe, F. L. H., van der Zwaag, P. A., Glaudemans, A. W. J. M., Oerlemans, M. I. F. J., Knackstedt, C., Michels, M., Hirsch, A., Hazenberg, B. P. C., Slart, R. H. J. A., Nienhuis, H. L. A.

“…Purpose There is a need for early quantitative markers of potential treatment response in patients with hereditary transthyretin (ATTRv) amyloidosis to guide…”
Get full text

Human versus porcine mesenchymal stromal cells: phenotype, differentiation potential, immunomodulation and cardiac improvement after transplantation by Noort, W. A., Oerlemans, M. I. F. J., Rozemuller, H., Feyen, D., Jaksani, S., Stecher, D., Naaijkens, B., Martens, A. C., Bühring, H. J., Doevendans, P. A., Sluijter, J. P. G.

“…Although mesenchymal stromal cells (MSCs) have been applied clinically to treat cardiac diseases, it is unclear how and to which extent transplanted MSCs exert…”
Get full text

Characteristics and outcomes of COVID-19 in heart transplantation recipients in the Netherlands by Muller, S. A., Manintveld, O. C., Szymanski, M. K., Damman, K., van der Meer, M. G., Caliskan, K., van Laake, L. W., Oerlemans, M. I. F. J.

“…Background Immunocompromised patients are at high risk of complicated severe acute respiratory coronavirus 2 infection. The aim of this retrospective study was…”
Get full text

A routine intervention in a highly unusual vessel by Gasecka, A., Voskuil, M., de Waal, E. E. C., Oerlemans, M. I. F. J., Ramjankhan, F., van Laake, L. W., Kraaijeveld, A. O.

Get full text

Circulating MicroRNAs as Novel Biomarkers for the Early Diagnosis of Acute Coronary Syndrome by Deddens, J. C., Colijn, J. M., Oerlemans, M. I. F. J., Pasterkamp, G., Chamuleau, S. A., Doevendans, P. A., Sluijter, J. P. G.

“…Small non-coding microRNAs (miRNAs) are important physiological regulators of post-transcriptional gene expression. miRNAs not only reside in the cytoplasm but…”
Get full text

One-year mortality after a first visit to a cardiology outpatient clinic: a useful performance indicator? by Oerlemans, M. I. F. J., Lok, D. J. A., Cornel, J. H., Mosterd, A.

“…Purpose In 2003 the Dutch Health Care Inspectorate introduced performance indicators to monitor and compare quality of care in Dutch hospitals. In 2007, the…”
Get full text

Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis by Muller, S A, Peiro-Aventin, B, Biagioni, G, Tini, G, Saturi, G, Knackstedt, C, Dobner, S, Michels, M, Merlo, M, Nitsche, C, Longhi, S, Musumeci, B, Cappelli, F, Garcia-Pavia, P, Oerlemans, M I F J

“…Abstract Background The 2021 European Society of Cardiology (ESC) screening recommendations for individuals carrying a pathogenic transthyretin amyloidosis…”
Get full text